Carrillo-Esper R, Chablé-Montero F, Zepeda-Mendoza AD, Gutiérrez-Grobe Y

Language: Spanish
References: 18
Page: 169-175
PDF size: 380.37 Kb.

ABSTRACT

Helicobacter pylori is a spiral Gram negative bacteria that colonize more than 50% of world population. This infection is acquired at an early age primarily by oral-oral or fecal-oral routes. In Mexico 5-9 year-old age group has a prevalence of 43% and in adult population the prevalence is 70-90%. H. pylori infection has a direct relationship with gastroduodenal ulcer development, gastric cancer, gastric mucosa-associated lymphoid tissue and colon, as well as various extraintestinal manifestations. Helicobacter pylori was described by Robin Warren and Barry Marshall in 1982, They won the Medicine Nobel Prize in 2005. The aim of this paper is to describe the case of a patient who developed anemia syndrome and thrombocytosis secondary to Helicobacter pylori infection, and review current concepts related to this interesting association.

REFERENCES

1. Shamah T, Villalpando S, Rivera JA. Resultados de Nutrición de la ENSANUT 2006. Instituto Nacional de Salud Pública, 2007.

2. Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Curr Opin Hematol 2005; 12: 123-8.

3. Muñoz M, Campos A, García J, Ramírez G. Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas. Nefrología 2005; 25: 9-19.

4. Mandel J, Church T, Bond J, Ederer F, Geisser M, Mongin S, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer. N Eng J Med 2000; 343: 1603-7.

5. Goodwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am 1993; 22: 5-19.

6. Hentze M. Iron regulatory factor-the conductor of cellular iron regulation. 27th Annual Course Advan Haematol 1993: 36-48.

7. Everhart J, Kruszon D, Perez I. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000; 181: 1359.

8. Shiotani A, Graham D. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002; 86: 1447-66.

9. Nakayama Y, Graham D. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther 2004; 2: 599-610.

10. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8.

11. Leal Y, Torres J, Perez G, Gomez A, Monath T, Tapia R, et al. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Am J Trop Med Hyg 1999; 60: 587-92.

12. Suerbaum S, Michetti P. Helicobacter pylori infection. N Eng J Med 2002; 347: 1175-86.

13. Cárdenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006; 163: 127-34.

14. Kawamata T, Tojo A. Helicobacter pylori-induced thrombocytosis clinically indistinguishable from essential thrombocythemia. Leuk Lymphoma 2012; 53: 1423-4.

15. Canducci F, Cremonini F, Armuzzi A. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 2002; 34(Suppl. 2): S81-S83.

16. Di Mario F, Aragona G, Bo ND, Ingegnoli A, Cavestro GM, Moussa AM, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 706-10.

17. Di Mario F, Aragona G, Bo ND, Ingegnoli A, Cavestro GM, Moussa AM, et al. Use of lactoferrin for Helicobacter pylori eradication. J Clin Gastroenterol 2003; 36: 396-8.

18. Duck W, Sobel J, Pruckler J. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-94.